The expected FDA decision on oral semaglutide for obesity (anticipated Q4 2025) is a potential catalyst for further portfolio expansion, market leadership reinforcement, and revenue growth
Its kind of amazing
Das S, Datta A, Bagchi C, Chakraborty S, Mitra A, Tripathi SK
Ardissino M, Vincent M, Hines O, Amin R, Eichhorn C, Tang AR, et al
The supplement, developed by Nutrapharm, marks the first time a finished product containing Setria has received formal health authority approval in Chile a significant milestone for the ingredient and for Chile's rapidly growing dietary supplement market
Now with a looming ban, many of the patients having success losing weight or treating their diabetes on both brand name and compounded medications will suffer if supply is not improved